Mupirocin NEW

Factory Provide High Quality Mupirocin / Bactoderm / Bactroban Ointment CAS 12650-69-0

Introduction

Product Name: Mupirocin 

Other Name :MUPIROCIN CALCIUM;Bactoderm;Bactroban Ointmen

CAS NO:12650-69-0

Purity: 99%min
Appearance:White Powder

MF:C26H44O9

MW:500.62

Melting Point :77-78°C (dec.)

Boiling Point :672℃

Density :1.183±0.06 g/cm3(Predicted)

Solubility :Soluble in DMSO or methanol. Sparingly soluble in water

Storage:Keep in dark place,Inert atmosphere,Room temperature

Mupirocin is an antibiotic of the monoxycarbolic acid class.
Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations. It is used topically and is effective againstGram-positive bacteria, including MRSA.
Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90% of the mixture. Also present in mupirocin are pseudomonic acid B with an additional hydroxyl group at C8,pseudomonic acid C with a double bond between C10 and C11, instead of the epoxide of PA-A, and pseudomonic acid D with a double bond at C4` and C5` in the 9-hydroxy-nonanoic acid portion of mupirocin.

Function:
The product of a variety of Gram-positive bacteria associated with skin infections especially staphylococcus and streptococcus highly sensitive to resistant Staphylococcus aureus is also effective. Certain Gram-negative bacteria have some antibacterial effect.With no cross-resistance to other antibiotics.
Infections of skin and soft tissue caused by Gram-positive cocci, such as impetigo, boils, folliculitis primary infection and eczema, dermatitis, ulcers, and other skin trauma secondary infection.
Application of Mupirocin :

Mupirocin Calcium is used to treat infected cuts or wounds. It is an antibiotic that works by stopping the growth of certain bacteria.
Mupirocin is used as a topical treatment for bacterial skin infections, for example, furuncle, impetigo, open wounds, etc. It is also useful in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), which is a significant cause of death in hospitalized patients having received systemic antibiotic therapy. It is suggested, however, that mupirocin cannot be used for extended periods of time, or indiscriminately, as resistance does develop, and could, if it becomes widespread, destroy mupirocin's value as a treatment for MRSA. It may also result in overgrowth of non-susceptible organisms.